LY007

DRUG2 trials

Sponsors

Shanghai Longyao Biotechnology Inc., Ltd., Ruijin Hospital

Conditions

B-NHL

Phase 1

An Evaluation of LY007 Cell Injection for r/r B-NHL

RecruitingNCT06279611

Shanghai Longyao Biotechnology Inc., Ltd.B-NHL

Start: 2021-12-25End: 2026-05-31Target: 18Updated: 2024-02-28

An Evaluation of LY007 Cell Injection for r/r B-NHL

RecruitingNCT06364852

Ruijin HospitalB-NHL

Start: 2021-12-25End: 2026-05-31Target: 18Updated: 2024-04-15

Related Papers

A phase 1 study of LY007, a novel anti-CD20 CAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Journal of Clinical Oncology2024-06-013 citations